Opdivo Overtakes Keytruda, Fueled By Lung Cancer Use
This article was originally published in Scrip
Thanks in part to a new indication in lung cancer and despite a later start on the market, Bristol-Myers Squibb Co.'s anti-PD1 Opdivo tripled its sequential sales in the second quarter, edging ahead of Merck & Co. Inc.'s competing Keytruda.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.